ProCE Banner Activity

Outcomes of Dolutegravir Use in Children and Adolescents Living With HIV-1 in Sub-Saharan Africa

Slideset Download
Conference Coverage
Large, retrospective analysis illustrates viral suppression with and tolerability of dolutegravir-based regimens in children and adolescents who were treatment naive or suppressed on previous regimens.

Released: July 22, 2021

Expiration: July 21, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner